semaglutide for metabolic syndrome (and Tirzepatide) in Obesity, Diabetes and Syndrome: Use, Misuse and Effective Strategies A Diabetic Male with Metabolic

10.15252/embr.202052146 42 ChenS.ZhaoY.LiuS.ZhangJ.AssarafY

Parents allege that prescribing physicians and drug companies failed to adequately warn about the increased risk of gastrointestinal disorders, prolonged vomiting, and other serious health complications in younger patients

Summary: Retatrutide affects three receptors: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR), and the glucagon receptor (GCGR), making it an investigational triple receptor agonist

doi: 10.1111/all.14879 146 SkurikhinEGPershinaOVPakhomovaAVPanESKrupinVAErmakovaNNet al

Steculorum, S

The potential for mu-opioid receptor agonists to be anti-emetic in humans: a review of clinical data